PRPH, US74345W2070

Shyam Venkatesan reports 5.48 percent stake in ProPhase Labs stock

Published on 10/21/2026 at 07:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The filing covers 855,101.981 shares dated October 16, 2026, with sole voting power. ProPhase Labs stock last closed at USD 0.01 on October 19, 2026.

Ownership filing reaches the market

Shyam Venkatesan reported a 5.48 percent ProPhase Labs stake in a filing dated October 16, 2026.
The position covered 855,101.981 shares with sole voting and dispositive power.
ProPhase Labs stock last closed at USD 0.01 on October 19, 2026.

PRPH, US74345W2070, Illustration mit AI erstellt.

ProPhase Labs (US74345W2070) is facing a new ownership disclosure after Shyam Venkatesan reported a 5.48 percent stake in a Schedule 13G filing dated October 16, 2026. According to StockTitan on October 19, 2026, the reported position covered 855,101.981 shares of common stock.

Ownership details carry the story

The filing assigns Venkatesan sole voting power and sole dispositive power over 855,101.981 shares. It lists shared voting power and shared dispositive power at zero, giving the disclosure a clearly defined control profile rather than a jointly held position.

The filing also identifies ProPhase Labs, Inc. as the issuer and its common stock as the security class. The disclosure is a regulatory ownership event, not a company earnings announcement or a new operating forecast.

What does 5.48 percent mean?

The stake crosses the 5 percent reporting threshold by 0.48 percentage points. For investors, the key information is the combination of the ownership percentage and the sole voting and dispositive authority attached to the reported position.

Business and trading context

ProPhase Labs describes itself as a biotech, genomics and consumer products company. Its investor-relations page identifies PRPH and lists second-quarter 2026 results for the quarter ended June 30, 2026, alongside the company's fiscal-year 2025 filing.

The company operates in the healthcare field, with diagnostics and research identified as its industry. On the US listing, ProPhase Labs last closed at USD 0.01 on October 19, 2026. The ownership filing therefore supplies the latest dated corporate development in this report, while the quotation provides a separate market reference.

Stock reference

The ownership disclosure is dated October 16, 2026, and the filing was reported on October 19, 2026. The next investor-relevant milestone shown by the company is its second-quarter 2026 reporting period, which ended June 30, 2026.